Duoneb adverse effects
Pro Research Analysisby 
Searched over 200M research papers
Analyzed relevant papers
Duoneb Adverse Effects: Key Safety and Side Effect Insights
Common Adverse Effects of Duoneb (Ipratropium Bromide and Albuterol)
Duoneb is a combination inhalation medication containing ipratropium bromide and albuterol, commonly used for chronic obstructive pulmonary disease (COPD) and other respiratory conditions. However, none of the provided research papers directly discuss Duoneb or its adverse effects. The studies instead focus on similarly named drugs or combination therapies, such as DuoBody-CD40×4-1BB, DUO-207, DUO-E, and Duonase, which are unrelated to Duoneb.
Adverse Effects in Related Combination Therapies
Immunotherapy and Oncology Combinations
- DuoBody-CD40×4-1BB (GEN1042): In a clinical trial for advanced solid tumors, the most common treatment-related adverse effects were fatigue (22%), fever (16%), nausea (10%), and elevated liver enzymes (10%). Severe (grade ≥3) adverse events were rare, with only 6% experiencing significant transaminase elevation. No severe thrombocytopenia was reported, and the safety profile was considered favorable overall .
- DUO-207 (Gemcitabine and Paclitaxel Nanomedicine): In preclinical studies with canines, DUO-207 caused dose-dependent blood-related toxicities but did not show signs of liver or kidney toxicity. Clinical observations were improved compared to standard treatments .
- DUO-E (Durvalumab, Carboplatin/Paclitaxel, ± Olaparib): In patients with endometrial cancer, the most common adverse events were anemia, nausea, and fatigue, mostly low grade. Some patients experienced serious blood-related side effects, such as pure red-cell aplasia and autoimmune hemolytic anemia, but these were rare. The overall safety profile was manageable and consistent with known effects of the drugs involved .
Nasal Spray Combination (Duonase)
- Duonase (Fluticasone and Azelastine Nasal Spray): Among users, 29% reported side effects, with headache (14%), cough (8%), and altered taste (dysgeusia, 6%) being the most common. No cases of excessive drowsiness (somnolence) were observed. The study suggests that patients experiencing headaches or coughs should be reassured about the safety of the medication, and those with nosebleeds should be monitored and educated on nasal hygiene .
Conclusion
While none of the studies directly address Duoneb, the reviewed research on similarly named combination therapies highlights that common adverse effects often include fatigue, headache, cough, nausea, and blood-related toxicities. Most side effects are mild to moderate, with serious events being rare and generally manageable. For specific information on Duoneb, it is important to consult dedicated studies or product information, as the above findings pertain to other combination therapies with different active ingredients.
Sources and full results
Most relevant research papers on this topic
1
1
493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors
DuoBody-CD404-1BB shows potential in enhancing tumor-specific immunity and may be a promising treatment for advanced solid tumors.
2021·
3citations
·M. Johnsonet al.Journal for ImmunoTherapy of Cancer
PDF
2
2
2555 Immune Check Point Inhibitor Enteritis: A Case of Severe Duodenitis From Nivolumab Therapy
Nivolumab-associated duodenitis, a rare immune-related adverse event, can be effectively treated with infliximab, a potential treatment for steroid-resistant cases.
Case ReportVery Rigorous Journal
2019·
1citation
·Erin S. Keyeset al.American Journal of Gastroenterology
3
3
Toxicology and clinical protocol development of DUO-207: An ultrasmall nanomedicine co-delivering gemcitabine and paclitaxel for the treatment of metastatic pancreatic cancer.
DUO-207 is a novel ultrasmall nanomedicine that can co-deliver paclitaxel and gemcitabine in a single intravenous infusion for treating stroma-rich cancers, with dose-dependent hematological toxicities but improved clinical observations compared to standard of care.
2025·
0citations
·Katherine Eichingeret al.Journal of Clinical Oncology
4
4
Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.
Durvalumab + carboplatin/paclitaxel followed by durvalumab olaparib showed significant progression-free survival improvement in endometrial cancer patients, with most common adverse events being low grade and leading to few treatment discontinuations or dose modifications.
RCT
2024·
1citation
·J. Thomes Pepinet al.Journal of Clinical Oncology
5
5
SIDE EFFECTS AMONG DUONASE (FLUTICASONE WITH AZELASTINE COMBINATION) NASAL SPRAY USERS
Most DUONASE nasal spray users experience headaches and coughs as side effects, indicating that users with headache and cough should be reassured of safety and followed up frequently for epistaxis.
2023·
0citations
·Nandanavanam V N P Sai Sarath Chanet al.GLOBAL JOURNAL FOR RESEARCH ANALYSIS
6
6
Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials
Halobetasol propionate/tazarotene combination lotion is an effective and safe treatment for plaque psoriasis, with more patients achieving treatment success and fewer side effects compared to HP, TAZ, or vehicle-treated controls.
Systematic Review
2020·
8citations
·V. Ramachandranet al.Annals of Pharmacotherapy
7
7
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Duvelisib demonstrated high response rates, good durability, and a manageable safety profile in patients with relapsed/refractory CLL/SLL who progressed on ofatumumab, including high-risk disease and disease previously refractory to ofatumumab.
Non-RCT
2020·
41citations
·M. Davidset al.Clinical Cancer Research
PDF
8
8
Efficacy Of Ipratropium Bromide/Albuterol Compared To Home Metered-Dose Inhalers For Inpatient Management Of Asthmatics
Ipratropium bromide/albuterol nebulizer (Duoneb) is more effective than home metered-dose inhalers for inpatient asthma management.
2024·
0citations
·Valerie Jaroenpuntaruket al.Journal of Allergy and Clinical Immunology
PDF
9
9
Polystyrene nanoplastics deteriorate LPS-modulated duodenal permeability and inflammation in mice via ROS drived-NF-κB/NLRP3 pathway.
Polystyrene nanoparticles (PSNPs) exacerbate LPS-induced inflammation and increase permeability in mice's duodenum through the ROS-driven NF-B/NLRP3 pathway.
Non-RCTAnimal StudyHighly Cited
2022·
125citations
·Yujiao Heet al.Chemosphere
10
10
Adverse Events of the Duodenal-Jejunal Bypass Liner: a Systematic Review
Adjustments to the anchoring system of the duodenal-jejunal bypass liner are needed to improve the safety margin and reduce adverse events.
Systematic ReviewRigorous Journal
2018·
48citations
·B. Betzelet al.Obesity Surgery